Free tool
FAERS Monitor: Bss
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020742 or its brand name (Bss, Calcium Chloride, Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, Sodium Citrate). Reports on generic versions are filed under their own applications.
Reports
1,293
Serious
1,129
87% of reports
Hospitalization
117
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- toxic anterior segment syndrome509
- endophthalmitis313
- hypopyon109
- eye inflammation100
- corneal oedema99
- off label use86
- post procedural complication79
- vision blurred74
- eye pain70
- anterior chamber cell63
- visual acuity reduced55
- visual impairment54
- anterior chamber fibrin47
- ocular hyperaemia45
- vitritis44
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 3 |
| 2006 | 79 |
| 2007 | 36 |
| 2008 | 46 |
| 2009 | 36 |
| 2010 | 24 |
| 2011 | 37 |
| 2012 | 104 |
| 2013 | 83 |
| 2014 | 69 |
| 2015 | 88 |
| 2016 | 132 |
| 2017 | 116 |
| 2018 | 66 |
| 2019 | 36 |
| 2020 | 17 |
| 2021 | 58 |
| 2022 | 89 |
| 2023 | 35 |
| 2024 | 36 |
| 2025 | 51 |
| 2026 | 30 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,866 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| toxic anterior segment syndromeSignal | 509 | 14239.9 | 12811.3 | 3,858,613 |
| anterior chamber fibrinSignal | 47 | 9332.5 | 6547.5 | 272,858 |
| hypopyonSignal | 109 | 2468.4 | 2033.2 | 231,316 |
| anterior chamber cellSignal | 63 | 1575.7 | 1223.7 | 88,968 |
| endophthalmitisSignal | 313 | 895.3 | 810.2 | 264,272 |
| corneal oedemaSignal | 99 | 751.8 | 619.3 | 70,249 |
| vitritisSignal | 44 | 396.0 | 295.1 | 16,544 |
| eye inflammationSignal | 100 | 172.3 | 142.6 | 16,689 |
| post procedural complicationSignal | 79 | 67.2 | 54.2 | 5,068 |
| visual acuity reducedSignal | 55 | 27.0 | 20.8 | 1,350 |
| eye painSignal | 70 | 20.2 | 16.1 | 1,261 |
| ocular hyperaemiaSignal | 45 | 15.4 | 11.6 | 594 |
| vision blurredSignal | 74 | 8.8 | 7.0 | 505 |
| visual impairmentSignal | 54 | 7.1 | 5.5 | 278 |
| off label use | 86 | 1.6 | 1.3 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.